Eron, Joseph J <br/><br/>
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.  [electronic resource] 

 -  Lancet (London, England)  Jan 2010 
 - 396-407 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(09)62041-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Cholesterol, LDL--blood<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--blood<br/>HIV-1--drug effects<br/>Humans<br/>Lopinavir<br/>Male<br/>Middle Aged<br/>Pyrimidinones--adverse effects<br/>Pyrrolidinones--adverse effects<br/>RNA, Viral--blood<br/>Raltegravir Potassium<br/>Ritonavir--adverse effects<br/>Treatment Outcome<br/>Viremia--physiopathology